Companies: 10,795·Total market cap: $144.5T
RxSight, Inc.

RxSight, Inc.

RXSTNASDAQHealthcare● Active
$4.95
$-0.05(-1.00%)
Market Cap$204913215
P/E Ratio
52W High$16
52W Low$4.7

RxSight, Inc. (RXST) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

rxst · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for RxSight, Inc. (RXST) measures how much investors pay for each dollar of the company's trailing earnings. RXST's current PE ratio of N/A is calculated by dividing its stock price of $4.95 by its TTM earnings per share of -$1.13.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-1.42
Based on 5 analysts
EPS (TTM)
-$1.13
TTM · diluted EPS
PEG Ratio
0.10
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RxSight, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 6.7x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Devices · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
RxSight, Inc.
RxSight, Inc.You
RXST
$205MN/A-$1.13
Butterfly Network, Inc.
Butterfly Network, Inc.
BFLY
$1.3BN/A-$0.31
Cerus Corporation
Cerus Corporation
CERS
$521MN/A-$0.08
Delcath Systems, Inc.
Delcath Systems, Inc.
DCTH
$378M134.00x$0.08
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc.
DMAC
$302MN/A-$0.70
OrthoPediatrics Corp.
OrthoPediatrics Corp.
KIDS
$468MN/A-$1.69
NeuroPace, Inc.
NeuroPace, Inc.
NPCE
$533MN/A-$0.66

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.95
2024-12-31
FY2024
$-0.71
2023-12-31
FY2023
$-1.41
2022-12-31
FY2022
$-2.41
2021-12-31
FY2021
$-1.78
2020-12-31
FY2020
11.07x$1.45+357.7%
2019-12-31
FY2019
2.42x$6.62

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for RxSight, Inc. (RXST) measures how much investors pay for each dollar of the company's trailing earnings. RXST's current PE ratio of N/A is calculated by dividing its stock price of $4.95 by its TTM earnings per share of -$1.13.

PE Ratio = Stock Price ÷ EPS (TTM)
= $4.95 ÷ -$1.13 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

RXST pe ratio · 6 questions

RXST's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.95 and TTM EPS of -$1.13. Data sourced from Financial Modeling Prep via RXST's SEC 10-K and 10-Q filings.

RXST PE ratioWhat is RXST PE ratioCurrent PE ratio of RXSTRXST PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RxSight, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09